CRISPR Therapeutics to Establish R&D Operations in Cambridge, Massachusetts

CRISPR Therapeutics to Establish R&D Operations in Cambridge, Massachusetts

--Company Appoints Bill Lundberg, M.D., as Chief Scientific Officer--

April 07, 2015 08:00 AM Eastern Daylight Time

BASEL, Switzerland & CAMBRIDGE, Mass.--()--CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines for serious human diseases, today announced the appointment of Bill Lundberg, M.D., to Chief Scientific Officer to lead the Company's development programs and to spearhead the creation of its R&D operations in Cambridge, Massachusetts.

"We are committed to assembling the best and brightest to rapidly advance the promise of CRISPR-Cas9 into therapies that treat serious human diseases," commented Dr. Rodger Novak, Chief Executive Officer of CRISPR Therapeutics. "We welcome Dr. Lundberg to our senior team as we accelerate our programs on both sides of the Atlantic. He brings significant experience in successfully translating research to clinical applications."

"CRISPR-Cas9 is a breakthrough in our ability to treat serious diseases, and we are now focused on translating this discovery into important new therapies for patients," stated Dr. Lundberg. "Our new Cambridge, Massachusetts, location provides us with close access to our academic founders and their extensive networks, as well as a large pool of scientific talent to drive our discovery and development programs." The Cambridge, Massachusetts, facility will house R&D operations and business development. Current job openings are at with additional job openings being posted in the coming weeks.

About Dr. Lundberg

Dr. Lundberg brings a strong track record to CRISPR Therapeutics. At Alexion Pharmaceuticals he was Vice President and Head of Translational Medicine, overseeing the progression of numerous compounds from early research to clinical proof-of-concept. Previously, Dr. Lundberg held senior positions at Taligen Therapeutics, Genzyme and Wyeth (now Pfizer) and led development programs in various disease areas. Dr. Lundberg trained in internal medicine and oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. He holds a Bachelor of Science in biology from the Massachusetts Institute of Technology, an M.D. from Stanford Medical School, and an MBA from the University of Massachusetts Amherst.

About CRISPR Therapeutics

CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. We were launched out of the Basel-based Versant Ventures offices in 2013 and have undertaken translational development programs in several important disease areas with our collaborators in Europe and the US. Our vision is to cure serious human diseases at the molecular level using CRISPR-Cas9.


MacDougall Biomedical Communications
Michelle Avery, +1 781-235-3060
[email protected]
Anca Alexandru, +49 (89) 2424-3494
[email protected]


Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.